Loxof film-coated tablets 500 mg blister No. 5

Pharmacological properties

Pharmacodynamics. Levofloxacin is a synthetic antibacterial drug of the fluoroquinolone group, it is the s-enantiomer of the racemic mixture of the drug ofloxacin.

Mechanism of action: As a fluoroquinolone antibacterial drug, levofloxacin acts on the DNA gyrase and topoisomerase IV complex.

Pharmacodynamics. The degree of bactericidal activity of levofloxacin depends on the ratio of C max or AUC and the minimum concentration (MIC).

Mechanism of resistance. The main mechanism of resistance is due to mutations in the gyr-A genes. In vitro, there is cross-resistance between levofloxacin and other fluoroquinolones.

Due to its mechanism of action, there is usually no cross-resistance between levofloxacin and other classes of antibacterial agents.

Breakpoints: The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommended MIC breakpoints for levofloxacin that distinguish susceptible from intermediately susceptible (moderately resistant) organisms and intermediately susceptible from resistant organisms are listed in the MIC testing table below (mg/L).

EUCAST clinical MIC breakpoints for levofloxacin (20.06.2006):

1 The MIC breakpoint between susceptible and intermediately susceptible (moderately resistant) strains was increased from 1 to 2 to inhibit the growth of wild strains of this organism, demonstrating the variability of this parameter. The breakpoints apply to high-dose therapy.

2 Strains with MIC values above the breakpoint between susceptible and intermediately susceptible (moderately resistant) strains are very rare or have not yet been reported. Identification and antimicrobial susceptibility testing on any such isolate should be repeated and, if confirmed, the isolate sent to a research laboratory.

3 Non-species MIC breakpoints were determined based on pharmacokinetic/pharmacodynamic data and are independent of the distribution of MICs in specific species.